Business Description
Allogene Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US0197701065
Total Employee Number:
152Description
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.67 | |||||
Equity-to-Asset | 0.7 | |||||
Debt-to-Equity | 0.26 | |||||
Debt-to-EBITDA | -0.45 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 29 | |||||
3-Year EPS without NRI Growth Rate | 28.8 | |||||
3-Year FCF Growth Rate | 24.5 | |||||
3-Year Book Growth Rate | -34.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 5.22 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 29.64 | |||||
9-Day RSI | 40.87 | |||||
14-Day RSI | 44.71 | |||||
3-1 Month Momentum % | -34.56 | |||||
6-1 Month Momentum % | 4.09 | |||||
12-1 Month Momentum % | 41.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.65 | |||||
Quick Ratio | 9.65 | |||||
Cash Ratio | 9.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.7 | |||||
Shareholder Yield % | -3.65 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -53.74 | |||||
ROA % | -38.96 | |||||
ROIC % | -106.4 | |||||
3-Year ROIIC % | -91.74 | |||||
ROC (Joel Greenblatt) % | -147.14 | |||||
ROCE % | -41.56 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.75 | |||||
Price-to-Tangible-Book | 1.75 | |||||
EV-to-EBIT | -2.86 | |||||
EV-to-EBITDA | -3.07 | |||||
EV-to-Forward-Revenue | 2.09 | |||||
EV-to-FCF | -4.5 | |||||
| Price-to-Net-Current-Asset-Value | 3.11 | |||||
| Price-to-Net-Cash | 3.26 | |||||
Earnings Yield (Greenblatt) % | -34.97 | |||||
FCF Yield % | -15.95 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALLO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Allogene Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.77 | ||
| Beta | 0.6463 | ||
| 3-Year Sharpe Ratio | -0.16 | ||
| 3-Year Sortino Ratio | -0.25 | ||
| Volatility % | 67.48 | ||
| 14-Day RSI | 44.71 | ||
| 14-Day ATR ($) | 0.140811 | ||
| 20-Day SMA ($) | 2.0465 | ||
| 12-1 Month Momentum % | 41.27 | ||
| 52-Week Range ($) | 0.9842 - 4.46 | ||
| Shares Outstanding (Mil) | 345.15 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Allogene Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Allogene Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 17:00 | In 118 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 117 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-13 17:00 | In 33 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 32 days | ||
| General meeting for 2026 | 2026-06-18 08:00 | 1.96 (+3.16%) | ||
| H.C. Wainwright 4th Annual Cell Therapy Virtual Conference | 2026-06-09 | 1.85 (-2.89%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 05:10 | 2.05 (-5.09%) | ||
| TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA | 2026-05-26 12:30 | 2.00 (+2.04%) | ||
| First quarter earnings conference call for 2026 | 2026-05-13 17:00 | 2.30 (+0.66%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 2.30 (+0.66%) |
Show
Entries
Allogene Therapeutics Inc Frequently Asked Questions
What is Allogene Therapeutics Inc(ALLO)'s stock price today?
The current price of ALLO is $1.99. The 52 week high of ALLO is $4.46 and 52 week low is $0.98.
When is next earnings date of Allogene Therapeutics Inc(ALLO)?
The next earnings date of Allogene Therapeutics Inc(ALLO) is 2026-08-13 Est..
Does Allogene Therapeutics Inc(ALLO) pay dividends? If so, how much?
Allogene Therapeutics Inc(ALLO) does not pay dividend.
Guru Commentaries on NAS:ALLO
No articles.
Press Release
Articles on Allogene Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers